SDHD: A Potential Drug Target and Biomarker forSUC (G6392)

Target Name: SDHD

NCBI ID: G6392

SDHD

SDHD: A Potential Drug Target and Biomarker forSUC

Succinate-ubiquinone oxidoreductase (SDHD) is a cytochrome b small subunit enzyme that is involved in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. SDHD is a critical enzyme in the production of energy from food, and it is a known regulator of cellular processes such as cell growth, differentiation, and apoptosis.

Recent studies have identified SDHD as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In this article, we will explore the biology and function of SDHD, and discuss its potential as a drug target and biomarker.

The Citric Acid Cycle

The TCA cycle, also known as the Krebs cycle, is a central metabolic pathway that produces energy from food. It is a complex process that involves the breakdown of glucose and fatty acids into smaller molecules, such as carbon dioxide, water, and ATP. The SDHD enzyme is involved in the first step of the TCA cycle, also known as the citric acid cycle or TCA cycle, which is the production of citric acid.

During the citric acid cycle, SDHD catalyzes the transfer of two electrons from the cytochrome b6f complex to FAD, which is then used to form FADH2. This transfer of electrons is critical for the production of ATP, which is the energy currency of the cell. SDHD also plays a role in the production of NAD+, which is a critical coenzyme for many cellular processes, including DNA replication and protein synthesis.

SDHD as a Drug Target

SDHD has been identified as a potential drug target for various diseases due to its involvement in the production of ATP and NAD+. blockers of SDHD have been shown to increase ATP production and decrease NAD+ levels, which can lead to a range of cellular consequences, including increased cell proliferation, differentiation, and apoptosis.

One of the SDHD-related diseases that has been extensively studied is cancer. Many cancer cells are dependent on SDHD for the production of ATP and NAD+, which can lead to increased cell proliferation and survival. Therefore, inhibitors of SDHD have been shown to be effective in slowing the growth of cancer cells.

In addition to cancer, SDHD has also been identified as a potential drug target for neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and are often associated with increased levels of NAD+.

SDHD has been shown to play a role in the production of NAD+ in neurodegenerative diseases, and therefore, inhibitors of SDHD have been shown to be effective in treating neurodegenerative diseases.

SDHD as a Biomarker

In addition to its potential as a drug target, SDHD has also been identified as a potential biomarker for various diseases. The production of ATP and NAD+ by SDHD is regulated by various intracellular signaling pathways, including the TCA cycle, the electron transport chain, and the AMP-activated protein kinase (AMPK).

In conclusion, SDHD is a critical enzyme involved in the production of ATP and NAD+ in the citric acid cycle. Its inhibition has been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Therefore, SDHD is a promising target for future drug development.

Protein Name: Succinate Dehydrogenase Complex Subunit D

Functions: Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q)

The "SDHD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDHD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets